SURVIVAL OF MOUSE PANCREATIC-ISLET ALLOGRAFTS IN RECIPIENTS TREATED WITH ALLOGENEIC SMALL LYMPHOCYTES AND ANTIBODY TO CD40 LIGAND
SURVIVAL OF MOUSE PANCREATIC-ISLET ALLOGRAFTS IN RECIPIENTS TREATED WITH ALLOGENEIC SMALL LYMPHOCYTES AND ANTIBODY TO CD40 LIGAND
复制标题
DOI：
10.1073/pnas.92.21.9560
复制
发表时间：
1995-10-10
影响因子：
11.1
通讯作者：
ROSSINI, AA
中科院分区：
文献类型：
--
作者：
PARKER, DC;GREINER, DL;ROSSINI, AA
同种异体小淋巴细胞或T细胞耗尽的小淋巴细胞加上CD40配体（CD40L）的封闭抗体的联合治疗允许无限期胰岛移植物存活在37的40个受体，不同的胰岛供体在主要和次要的组织相容性位点。同种异体小淋巴细胞的作用是供体抗原特异性的。两种单独治疗都不如联合治疗有效，尽管抗CD40 L本身可以使40%的受者的胰岛移植物存活不确定。我们的解释是，在缺乏适当的共刺激信号的情况下，表达供体抗原的小淋巴细胞对同种异体反应性宿主细胞具有耐受性。抗CD40L抗体可阻止宿主T细胞在供者淋巴细胞或胰岛移植物中诱导共刺激信号。
Combined treatment with allogeneic small lymphocytes or T-depleted small lymphocytes plus a blocking antibody to CD40 ligand (CD40L) permitted indefinite pancreatic islet allograft survival in 37 of 40 recipients that differed from islet donors at major and minor histocompatibility loci. The effect of the allogeneic small lymphocytes was donor antigen-specific. Neither treatment alone was as effective as combined treatment, although anti-CD40L by itself allowed indefinite islet allograft survival in 40% of recipients. Our interpretation is that small lymphocytes expressing donor antigens in the absence of appropriate costimulatory signals are tolerogenic for alloreactive host cells. Anti-CD40L antibody may prevent host T cells from inducing costimulatory signals in donor lymphocytes or islet grafts.